Plasma fractionation market seen topping $56 billion by 2030

The plasma fractionation market is projected to exceed $56 billion by 2030, driven by rising demand for immunoglobulins, albumin and other plasma-derived therapies. The report points to North America and the U.S. as the largest markets, while CSL Limited remains the top global player.

Why it matters: - Plasma fractionation is moving deeper into mainstream pharma as demand rises for therapies used in immune deficiencies, bleeding disorders, autoimmune disease and other chronic conditions. - The market’s growth matters because it affects the supply of plasma-derived medicines used across hospitals, clinics and specialty care settings. - The segment is also becoming more competitive as companies race to expand collection networks, manufacturing capacity and product pipelines.

What happened: - The Business Research Company published its Plasma Fractionation Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report projects the plasma fractionation market will surpass $56 billion by 2030. - The market is expected to make up about 88% of the broader plasma protein therapeutics market, which is forecast near $63 billion by 2030. - Within the wider pharmaceuticals industry, expected to reach $2,496 billion in 2030, plasma fractionation is projected to account for close to 2% of market value. - CSL Limited leads global sales in the market with an 11% share in 2025. - Grifols S.A. introduced Yimmugo in the U.S. in October 2025, a sugar-free, ready-to-use IVIg product developed by Biotest AG.

The details: - Immune disorders and rare diseases are a major growth driver, including immunodeficiency, autoimmune and neurological disorders, hemophilia and hereditary angioedema. - Greater diagnostic capability and awareness are expanding access to plasma-derived treatments such as immunoglobulins and coagulation factors. - Broader clinical adoption is also supporting growth across immunology, hematology, neurology and critical care. - Expanded plasma collection networks, new donation centers, upgraded fractionation facilities, better purification methods and improved cold-chain logistics are helping address supply shortages. - Immunoglobulins are the largest product segment and are forecast to represent 46% of the market, or about $26 billion, by 2030. - The market also includes applications in hemato-oncology and rheumatology. - End users include hospitals and clinics, clinical research labs and academic institutions. - North America is expected to remain the largest regional market, reaching $23 billion by 2030 from $15 billion in 2025. - The U.S. is projected to lead North America at $22 billion in 2030, up from $14 billion in 2025. - The top 10 companies held 28% of total revenue in 2025, signaling a moderately fragmented market. - Key companies listed include CSL Limited, Grifols S.A., Takeda Pharmaceutical Company, Octapharma AG, Kedrion S.P.A., China National Biotec Group, LFB Biomedicaments S.A.S., GC Biopharma Corp., Kamada Ltd. and ADMA Biologics Inc. - The report says the biggest opportunity areas through 2030 are immunoglobulins, albumin, coagulation factors and protease inhibitors, which together are expected to add more than $21 billion in value. - Immunoglobulins are expected to grow by $10 billion, albumin by $5 billion, coagulation factors by $4 billion and protease inhibitors by $2 billion between 2025 and 2030.

Between the lines: - The market is benefiting from structural demand, not just short-term product cycles, because plasma therapies are tied to long-term treatment needs. - High regulatory and manufacturing barriers help protect incumbents and make scale a competitive advantage. - The concentration data suggest room for consolidation or partnership activity as companies look to secure plasma supply and expand production. - Product innovation is increasingly centered on convenience and access, not only clinical efficacy, as shown by ready-to-use IVIg formats.

What's next: - Companies are likely to keep investing in fractionation technology, purification efficiency, automation and traceability. - Expansion of plasma donation infrastructure should remain a key strategy to reduce supply constraints. - New therapeutic indications and personalized treatment approaches may add more demand through 2030. - Regional leadership is expected to stay with North America and the U.S. unless other markets accelerate collection and manufacturing capacity.

The bottom line: - Plasma fractionation is evolving from a niche biologics segment into a high-growth, infrastructure-heavy market anchored by immunoglobulins, strong U.S. demand and a small group of dominant global players.